This study is testing a new medicine called NBI-1117568 to see if it can help prevent the return of symptoms in adults with schizophrenia, a mental health disorder that affects how a person thinks and acts. The study compares NBI-1117568 to a placebo, which is a pill with no active medicine, after patients have shown improvement with NBI-1117568.
Key Points:
- Length of Study: Patients need to have had schizophrenia for at least a year before joining.
- Eligibility: You should have responded well to other antipsychotic therapies before, except clozapine.
- Health Status: You should not have any unstable medical conditions or significant untreated diseases.
Please note, other specific criteria may apply for participation. Ensure you're comfortable with the conditions and requirements before considering participation. If you have any current health issues or have recently stayed in a psychiatric facility, discuss with the medical team to see if it affects your eligibility.
How understandable was the trial content above?
Hard to understand
Easy to understand